Home
overview

Following on from our hugely successful Cell-Based Assays conference in 2011 SMi will provide a global forum for senior level decision makers and those working within Cell-Based Assays to meet.
 

Cell-Based Assays 2012 will show recent developments in ion channels, stem-cell platforms, label free assays and 3D cell culture.
Recalls with drugs due to toxicity can cause R&D costs to spiral and can lead to huge wastes in research time. Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years. Recent increases in therapeutic use of stem cells has allowed increases in toxicity accuracy, also preventing the use of animal testing and cancerous cells

Our 3-day event, formed of two half day post-conference workshops and a two-day conference will provide useful insights into the latest developments within Cell Based Assays. With an international array of speakers, enhance product launches or your own new developments with key decision makers from big pharma, biotech and academia.

Cancerous cell based assays poorly represent normal cellular physiology and thus provide inadequate, inaccurate data on preclinical drug toxicity testing. 3D cell based assays have been developed to try and change that. Explore the newest techniques in 3D cell culture by those developing the technology with recent successes. Ion channels as drug targets are playing a huge role in new drug discovery – over half of the new drugs coming to market are based around ion channel interaction. We discover, at cell based 2012, the latest approaches in ion channel drug discovery.

  • Hear about the latest techniques, technologies and methods being utilised in cell-based assays
  • Engage with those currently working on producing label free assays
  • Discuss the latest assays in use with stem cells
  • Explore new target identification and how to get your results earlier
  • Learn from a wide array of industry specialists on 3D cell culture and Ion Channel developments
  • Network with key industry associates and solution providers to share valuable experiences

 

  • Screening 
  • Pre-clinical Research 
  • Pharmacology 
  • Lead discovery technologies 
  • Molecular and cellular biology 
  • Biological technologies 
  • Lead generation and optimization 
  • High-content analysis 
  • Target identification and validation 
  • Target discovery 
  • In vitro assays 
  • Compound profiling 
  • Assay development 

Abbott France S A (Absorbed Laboratories Knoll); Abcellute Ltd; Ablynx; ainia Centro Tecnologico; ALMIRALL; AstraZeneca; BD Biosciences; BD Biosciences - Cell Analysis; BioFocus Plc; Biostatus Ltd; BTG; Cancer Research UK; Carna Biosciences; Chromocell Corporation; Crucell; Cytoo S.A.; Eli Lilly & Co; Empa - Swiss Federal Laboratories for Materials Science and Technology; Geistlich Pharma AG; Genedata; Genentech; Genetic Engineering News; Genzyme Corporation; GlaxoSmithKline; GSK; Hoffmann-La Roche; Imperial College London; INSERM U634; Institute of Cancer Research; Kinase Logistics; Kings College London; Life Technologies Limited; Max Cyte Inc; MaxCyte Inc; MaxCyte, Inc.; MedImmune; Merck & Company Incorporated Usa; Merz Pharmaceuticals GmbH; National Institute For Biological Standards And Control; NIBSC; Novartis; Novartis Horsham Research Centre; Novartis Pharmaceuticals; Novo Nordisk; Novo Nordisk A S; Noxxon Pharma AG; Orion Corporation Orion Pharma; Pfizer; Pfizer Ltd; Plasticell; Queen Mary And Westfield College; Reinnervate; Roche; The Electrospinning Company; The Insitiute of Cancer Research: Royal Cancer Hospital; The University of Buckingham; Thrombogenics N V; University College London Medical School; University Of Birmingham; University of Hertfordshire; University of Leeds;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Nathan  Bays

Nathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa

9:10 Taking a 3 Dimensional approach to cell based assays

Anthony Davies

Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

  • Why are 3D cell culture and assay technologies considered better than conventional 2D
  • When and how should these assays be deployed into your research programme
  • What currently is available and how it is being used
  • 9:45 Alvetex 3D cell culture technology and applications for high throughput screening of liver toxicity and cancer assays

    Stefan Przyborski

    Stefan Przyborski, Founder and CSO, Reinnervate

  • Conventional 2D cell culture models provide poor proxy for real tissues, where does 3D take us
  • Alvetex technology has been developed as a solution for simple and routine 3D cell culture that adds significant value to the culture model
  • Alvetexand applications including liver toxicity, cancer cell biology, and physiologically relevant cell based assays
  • Demonstrations in application for use in validation and high throughput studies
  • 10:25 Morning Coffee

    10:55 Tecan’s Infinite® 200 PRO – the reader with integrated cell incubator

    Christian Oberdanner

    Christian Oberdanner, Marketing Application Specialist, Tecan Austria GmbH

  • How often do you transfer your microplate between the incubator and plate reader
  • Simultaneous, independent adjustment of CO2 and O2
  • Consistent physiological conditions for predictable culture growth
  • True walkway operation reducing labor time & improving productivity
  • No gaps in data during overnight or long running experiments
  • 11:35 Comparison of different 3D cell culture models for their application in high throughput screening

    Rosalia Arrebola

    Rosalia Arrebola, Scientist, Lead Identification Technologies & Kinases, Sanofi Aventis

  • Pragmatic approaches for high throughput screening
  • 2D verses 3D
  • 3D kinase cell based assays
  • 12:10 Networking Lunch

    13:10 3D tumour spheroids for drug discovery in oncology

    Carsten Wenzel

    Carsten Wenzel, Scientist, Bayer

  • Advances in high content screening on 3D tumour spheroids
  • 3D assay development
  • Tumour micro environment
  • 13:45 A Novel, Rapid and Reproducible Method for Creating 3D Cell Cultures to Study Complex Cell Behavior

    Grant Cameron

    Grant Cameron, Development Director, TAP Biosystems

  • Ceating complex 3D cell cultures in a simple, consistent & reproducible format
  • Using physiologically relevant collagen concentrations to create the most natural environment for cells
  • Enabling scientists to take complete control of their experiments by using their own cell type(s) and selecting seeding density
  • 14:25 Molecular Characterisation of the tumor stroma crosstalk using a novel 3D co-culture iv vitro model

    Albin Rudisch

    Albin Rudisch, Scientist, Boehringer Ingelheim Pharma Informacios Es Szerviz Iroda

  • Identifying molecular mechanisms in the cross talk between small cell lung cancer (NSCLC) and corresponding CAFs
  • Novel and complex 3D organtypic (spheroid) in vitro cell culture model system has been established
  • Advantages in vivo situation reflecting the complexity and dynamics of human tumors more faithfully than 2D monotypic monolayer cultures
  •  

     

     

    15:00 Afternoon Tea

    15:35 Roles of ion channels in cell-based drug discovery — New strategies and techniques enabling attrition reduction strategies

    David Standing

    David Standing, Senior Scientist, GlaxoSmithKline

  • Role of ion channels in attrition reduction strategy
  • Screening and triage strategies for characterizing on and off target ion channel activity
  • Enhanced capabilities of new electrophysiology platforms such as Barracuda to deliver reliable, robust, predicative and cost effective decision making data
  • 16:10 Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates

    Paul Groot-Kormelink

    Paul Groot-Kormelink , Investigator III, Novartis Pharmaceuticals

  • High throughput gene expression enabling re-evaluation of surrogate cell types for cellular models
  • Introductions to dynamically regulated families of integral membrane proteins
  • Similarities and differences in ion channel and g-protein couples receptors between alveolar macrophages and their surrogates
  • 16:50 Using GPCR signalling assays to study chemokine biology and develop novel anti-inflammatory drugs

    Asif Iqbal

    Asif Iqbal, Post-Doc Research Scientist, Oxford University

  • CC chemokine signalling followed by electrical cell-substrate impendence for sensing ECIS and beta arrestin recruitment
  • Label free assays for galphai couples GPCRs and screening for novel cannaboids active at the CB2 receptor
  • Development of real time chemotaxis
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    Nathan  Bays

    Nathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Nathan  Bays

    Nathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa

    9:10 Immortality breeds deceit: How is screening in primary cells has uncovered misleading data from cell lines common to therapeutic discovery

    Nathan  Bays

    Nathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa

    • Cell lines is a 'workhorse' in therapeutic discovery
    • Innovations in primary and stem cell technologies
    • Case studies of misleading cell line data and rescue of programmes by switching to primary cells

    9:50 Bringing phenotypic primary cell assays to the forefront of drug discovery

    Gareth Wayne

    Gareth Wayne, Investigator, GlaxoSmithKline

  • Increasing evidence that phenotypic assay approaches are more successful in developing first class drugs
  • Significant progress in both primary cell isolation and culture, together with assay technology improvements are enabling such assays to be deployed earlier in drug discovery processes
  • Examples of how such approaches are applied within GlaxoSmithKline
  • 10:30 Morning Coffee

    11:00 Label free detection of cell activation and cell adhesion

    Anker Jon Hansen

    Anker Jon Hansen, Scientific Director, ImmunoBiology, Novo Nordisk

    • Cell adhesion
    • Cell migration
    • Cell activation
    • Endothelial / Epithelial barrier function
    • Cell death

    11:40 Label free real time cellular assays using calorimetry

    Magnus Jansson

    Magnus Jansson, Chief Scientific Officer, SymCel Sverige AB

  • Introduction to calorimetry based assays
  • What information can be derived from heat flow - advantages and limitations
  • Calorimetry based cellular assays - application areas
  • The calScreener system intoduction
  • 12:20 Networking Lunch

    13:20 Design of end-point high throughput screening assays to monitor dynamic processes

    Robin Ketteler

    Robin Ketteler, Group Leader, University College London

    • Introductions through high-throughput, high content screening
    • Signal transduction
    • Luciferase assays
    • Protein secretion

    14:00 Comprehensive tools for GPCR pharmacology

    Xavier Leroy

    Xavier Leroy, Associate Director, Project Leader , Actelion Ltd.

    • G12/G13
    • Beta-arrestin 2
    • label-free
    • Deorphanisation

    14:40 Afternoon Tea

    15:10 Human Pluripotent stem cells in drug screening

    Dusko Ilic

    Dusko Ilic, Senior Lecturer in Stem Cell Science, Kings College London

    • Overview of current status of stem cells
    • Future perspectives of human embryonic stem cells
    • Induced pluripotent stem cell-based platforms in drug discovery

    15:50 Flow Cytometric screening of novel human breast stem/progenitor cells

    Mona Shehata

    Mona Shehata, Research Associate, Cancer Research UK - Sponsored by BD BioScience

  • Development of flow cytometric-based strategies for the identification and purification of human mamary stem, luminal progenitor and differentiated cells.
  • BD LyoplateTM Human Cell Surface Marker Screening Panel in conjunction with known markers to rapidy screendifferent breat cell subpopulations using hundreds of antibodies.
  • Identification of a number of potentially new novel cell markers and in-depth analysis
  • 16:30 Automated analysis of 3D cultures using high content screening

    Gareth  Griffiths

    Gareth Griffiths , Director, Imagen Biotech

    • Using the hanging drop method to grow and analyse 3D cell cultures for drug response
    • Measuring cancer stem cells through 3D colony formation
    • Current obstacles in 3D cell culture and how to overcome them

    17:10 Chairman’s Closing Remarks and Close of Day Two

    Nathan  Bays

    Nathan Bays, Principal Scientist, Pharmacology, Merck & Company Incorporated Usa

    +

    FEATURED SPEAKERS

    Albin Rudisch

    Albin Rudisch

    Scientist, Boehringer Ingelheim Pharma Informacios Es Szerviz Iroda
    Nathan  Bays

    Nathan Bays

    Principal Scientist, Pharmacology, Merck & Company Incorporated Usa
    Rosalia Arrebola

    Rosalia Arrebola

    Scientist, Lead Identification Technologies & Kinases, Sanofi Aventis
    Xavier Leroy

    Xavier Leroy

    Associate Director, Project Leader , Actelion Ltd.

    Albin Rudisch

    Scientist, Boehringer Ingelheim Pharma Informacios Es Szerviz Iroda
    Albin Rudisch

    Anker Jon Hansen

    Scientific Director, ImmunoBiology, Novo Nordisk
    Anker Jon Hansen

    Anthony Davies

    Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
    Anthony Davies

    Asif Iqbal

    Post-Doc Research Scientist, Oxford University
    Asif Iqbal

    Carsten Wenzel

    Scientist, Bayer
    Carsten Wenzel

    Christian Oberdanner

    Marketing Application Specialist, Tecan Austria GmbH
    Christian Oberdanner

    David Standing

    Senior Scientist, GlaxoSmithKline
    David Standing

    Dusko Ilic

    Senior Lecturer in Stem Cell Science, Kings College London
    Dusko Ilic

    Gareth Griffiths

    Director, Imagen Biotech
    Gareth  Griffiths

    Gareth Wayne

    Investigator, GlaxoSmithKline
    Gareth Wayne

    Grant Cameron

    Development Director, TAP Biosystems
    Grant Cameron

    Magnus Jansson

    Chief Scientific Officer, SymCel Sverige AB
    Magnus Jansson

    Mona Shehata

    Research Associate, Cancer Research UK - Sponsored by BD BioScience
    Mona Shehata

    Nathan Bays

    Principal Scientist, Pharmacology, Merck & Company Incorporated Usa
    Nathan  Bays

    Paul Groot-Kormelink

    Investigator III, Novartis Pharmaceuticals
    Paul Groot-Kormelink

    Robin Ketteler

    Group Leader, University College London
    Robin Ketteler

    Rosalia Arrebola

    Scientist, Lead Identification Technologies & Kinases, Sanofi Aventis
    Rosalia Arrebola

    Stefan Przyborski

    Founder and CSO, Reinnervate
    Stefan Przyborski

    Xavier Leroy

    Associate Director, Project Leader , Actelion Ltd.
    Xavier Leroy

    Workshops

    The culture and Analysis of Cells in 3 Dimensions
    Workshop

    The culture and Analysis of Cells in 3 Dimensions

    Copthorne Tara Hotel
    7th November 2012
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.